AN788 for treatment of depression

AN788 is a novel clinical candidate for second line treatment of Major Depressive Disorder (MDD). AN788 has a unique dual (serotonin-dopamine) reuptake inhibition profile distinct from the known plethora of monoamine reuptake inhibitors. AN788 has been administered to healthy volunteers in a single ascending dose study and in a PET study, demonstrating orderly pharmacokinetics and attaining levels of occupancy at serotonin and dopamine transporters that support its potential as a second line treatment for treating residual symptoms in MDD, such us fatigue, excessive sleepiness and lack of interest with a fast onset of action, and reduced sexual and cardiovascular side-effect profile. AN788 is ready for Phase I MAD studies with a partner or as an investment opportunity in spin-out.